130 related articles for article (PubMed ID: 38185519)
1. [Comparison of BCR::ABL (P210) mRNA levels detected by dPCR and qPCR methods in patients with chronic myeloid leukemia].
Gao HL; Hao Y; Chen WM; Li LD; Wang X; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):906-910. PubMed ID: 38185519
[No Abstract] [Full Text] [Related]
2. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
[TBL] [Abstract][Full Text] [Related]
3. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
4. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
[TBL] [Abstract][Full Text] [Related]
5. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
6. [Detection of
Ruan M; Zhang LL; Li YM; Li DY; Yuan ZY; Zheng ZZ; Zeng QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1647-1656. PubMed ID: 38071041
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
[TBL] [Abstract][Full Text] [Related]
8. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
9. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
10. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
11. [The influence of peripheral blood sample storage and delivery on the quantitative detection result of BCR-ABL (P210) transcript levels].
Hua MQ; He N; Zhong CQ; Yang XY; Liu JT; Wang RQ; Han FJ; Zhang C; Ma DX
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):224-229. PubMed ID: 33910308
[No Abstract] [Full Text] [Related]
12. [A multicenter study on the validation of conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia].
Qin Y; Lin Z; Cen J; Li X; Li Q; Cheng H; Geng S; Wang Y; Ma D; Qiao C; Li J; Li L; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):134-7. PubMed ID: 24606655
[TBL] [Abstract][Full Text] [Related]
13. [Study on mismatch repair genes of chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
[TBL] [Abstract][Full Text] [Related]
14. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
15. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
Arana-Trejo RM; Ruíz Sánchez E; Ignacio-Ibarra G; Báez de la Fuente E; Garces O; Gómez Morales E; Castro Granados M; Ovilla Martínez R; Rubio-Borja ME; Solís Anaya L; Herrera P; Delgado Llamas J; Kofman S
Clin Lab Haematol; 2002 Jun; 24(3):145-50. PubMed ID: 12067277
[TBL] [Abstract][Full Text] [Related]
16. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
17. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
18. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
20. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
